Ibba Luciano, Gargiulo Luigi, Bianco Matteo, Di Giulio Sara, Cascio Ingurgio Ruggero, Alfano Angela, Vignoli Carlo A, Valenti Mario, Facheris Paola, Perugini Chiara, Narcisi Alessandra, Costanzo Antonio
Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Clin Exp Dermatol. 2025 Apr 2. doi: 10.1093/ced/llaf144.
Janus kinase (JAK) inhibitors are widely used for treating atopic dermatitis (AD) and alopecia areata (AA). Weight gain is an emergent adverse event associated with JAK inhibitors, particularly those acting on the JAK2 pathway. We conducted a retrospective monocentric 2-cohort study, including 226 patients, to evaluate the prevalence of weight gain in patients with AD and AA who were treated with JAK inhibitors for at least one year. We included 142 patients in the JAK1/2 cohort (receiving upadacitinib 30 mg or baricitinib 4 mg) and 84 in the JAK1 cohort (receiving upadacitinib 15 mg or abrocitinib 100 mg). The JAK1/2 cohort showed an additional weight gain throughout the study period (at week 52: β=1.84, 95% C.I. 1.45-2.23, p<0.001). In conclusion, patients receiving JAK1/2 inhibitors for AD or AA are at a greater risk of weight gain than those treated with JAK1 inhibitors, likely due to impaired leptin signaling.
Janus激酶（JAK）抑制剂被广泛用于治疗特应性皮炎（AD）和斑秃（AA）。体重增加是与JAK抑制剂相关的一种新出现的不良事件，尤其是作用于JAK2通路的抑制剂。我们进行了一项回顾性单中心双队列研究，纳入226例患者，以评估接受JAK抑制剂治疗至少一年的AD和AA患者体重增加的发生率。我们将142例患者纳入JAK1/2队列（接受30 mg乌帕替尼或4 mg巴瑞替尼），84例纳入JAK1队列（接受15 mg乌帕替尼或100 mg阿布昔替尼）。JAK1/2队列在整个研究期间出现了额外的体重增加（第52周时：β=1.84，95%置信区间1.45-2.23，p<0.001）。总之，接受JAK1/2抑制剂治疗AD或AA的患者比接受JAK1抑制剂治疗的患者体重增加风险更高，这可能是由于瘦素信号受损所致。
